

Product Introduction

Losartan Potassium (DuP 753)

Losartan is an **angiotensin II receptor** antagonist, competes with the binding of angiotensin II to AT1 receptors with **IC50** of 20 nM.

Technical Data:

Molecular Weight (MW):	462.01	
Formula:	C22H23CIKN6O	CI N N N NH
Solubility (25°C)	DMSO 92 mg/mL	
* <1 mg/ml means slightly	Water 92 mg/mL	
soluble or insoluble:	Ethanol 92 mg/mL	
Purity:	>98%	
Storage:	3 years -20℃ Powder	
	6 months-80°Cin DMSO	
CAS No.:	124750-99-8	

Biological Activity

Losartan (180 mg/d) causes significant increases in plasma angiotensin II and angiotensin-(1-7) in monkeys with diet-induced hypercholesterolemia. Losartan (180 mg/d) reduces the extent of fatty streak in the aorta, the coronary arteries, and the carotid arteries by approximately 50% in monkeys with diet-induced hypercholesterolemia. Losartan reduces the susceptibility of LDL to in vitro oxidation, serum levels of monocyte chemoattractant protein-1, and circulating monocyte CD11b expression in monkeys with diet-induced hypercholesterolemia. [2] Losartan (0.6 g/L in their drinking water) prevents elastic Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk. This item is only for R&D purpose not for commercial business in kilos. Buyers should overview the patent issue in their countries.

fiber fragmentation and blunted TGF- β signaling in the aortic media in pregnant Fbn1C1039G/+ mice, as evidenced by reduced nuclear accumulation of pSmad2. Losartan (0.6 g/L in their drinking water) shows a reduction in distal airspace caliber in pregnant Fbn1C1039G/+ mice. Losartan (0.6 g/L in their drinking water) improves disease manifestations in the lungs, an event that cannot plausibly relate to improved hemodynamics in pregnant Fbn1C1039G/+ mice. [3] Losartan (5 mg/kg/d) leads to a significant decrease in the development of atherosclerotic lesions in the apo E deficient mice. Losartan (5 mg/kg/d) significantly reduces the susceptibility of the mice LDL to lipid oxidation following its incubation with CuSO4 in the apo E deficient mice. [4] Losartan (10 mg/kg) administration increases blood angiotensin levels four fold to six fold, blood BK levels are unchanged in male Sprague Dawley rats. Losartan (10 mg/kg) increases plasma renin levels 100-fold, plasma angiotensinogen levels decreases to 24% of control and plasma aldosterone levels are unchanged in male Sprague Dawley rats. [5]

Losartan has a major active metabolite, EXP 3174.

References

- [1] Burnier M, et al. Circulation, 2001, 103, 904-912.
- [2] Strawn WB, et al. Circulation, 2000, 101(13), 1586-1593.
- [3] Habashi JP, et al. Science, 2006, 312(5770), 117-121.
- [4] Hayek T, et al. Cardiovasc Res, 1999, 44(3), 579-587.
- [5] Campbell DJ, et al. J Cardiovasc Pharmacol, 1995, 26(2), 233-240.



Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk. This item is only for R&D purpose not for commercial business in kilos. Buyers should overview the patent issue in their countries.

